July 14, 2025

Is Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine of Clinical Utility?

CMCatia MarzoliniUniversity of Liverpool

Key Points

Therapeutic drug monitoring enhances understanding of drug levels in patients receiving cabotegravir and rilpivirine, aiding treatment efficiency.
Key evidence suggests that consistent monitoring can optimize therapeutic outcomes, particularly in HIV treatment.
This analysis assesses the method of therapeutic drug monitoring in clinical settings, indicating potential for improved patient management.
Findings call for further research on long-acting HIV therapies, emphasizing the clinical implications of effective drug monitoring.

Abstract

Journal Article Corrected proof Is Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine of Clinical Utility? Get access Catia Marzolini Catia Marzolini Service and Laboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, University Hospital Lausanne and University of Lausanne, Lausanne, SwitzerlandDivision of Infectious Diseases, Departments of Medicine and Clinical Research, University Hospital of Basel and University of Basel, Basel, SwitzerlandCentre for Experimental Therapeutics, University of Liverpool, Liverpool, United Kingdom Correspondence: C. Marzolini, Service and Laboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, University Hospital of Lausanne, Rue du Bugnon 17, Lausanne 1011, Switzerland (email protected). https://orcid.org/0000-0002-2312-7050 Search for other works by this author on: Oxford Academic PubMed Google Scholar Clinical Infectious Diseases, ciaf386, https://doi.org/10.1093/cid/ciaf386 Published: 18 August 2025 Article history Received: 27 June 2025 Editorial decision: 02 July 2025 Corrected and typeset: 18 August 2025 Published: 18 August 2025

Demander à l'IA

Bookmark

View Full Paper